Podcasts about Attribution

"The United States does not have a national cancer registry. We have a bunch of state registries. Some of those registries do collaborate and share information, but the issue is the registries that do exist typically do not report cancer by occupation. So, we cannot get our arms around the potential work-relatedness of the health outcome given the current way the state registries collect information. What we're trying to set up, is a way to make what is currently an invisible risk, visible," ONS member Melissa McDiarmid, MD, MPH, DABT, professor of medicine and epidemiology and public health director of the division of occupational and environmental medicine at the University of Maryland School of Medicine in Baltimore, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 23, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the incidence of hazardous drug exposure and the tracking and reporting of healthcare worker exposures. Episode Notes  Complete this evaluation for free NCPD. University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry information sheet ONS Podcast™ episodes: Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 308: Hazardous Drugs and Hazardous Waste: Personal, Patient, and Environmental Safety Episode 209: Updates in Chemo PPE and Safe Handling ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE National Hazardous Drug Exposure Registry Safeguards Oncology Professionals NIOSH Releases Its 2024 List of Hazardous Drugs Safe Handling—We've Come a Long Way, Baby! Strategies to Promote Safe Medication Administration Practices Surfaces in Patient Bathrooms Often Contaminated With HDs, Despite Use of Plastic-Backed Pads ONS books: Safe Handling of Hazardous Drugs (fourth edition) Safe Handling of Hazardous Drugs Quick Guide™ ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Hazardous Drug Exposure: Case Report Analysis From a Prospective, Multisite Study of Oncology Nurses' Exposure in Ambulatory Settings Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic Sequential Wipe Testing for Hazardous Drugs: A Quality Improvement Project The Use of Plastic-Backed Pads to Reduce Hazardous Drug Contamination Oncology Nursing Forum articles: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs Factors Influencing Nurses' Use of Hazardous Drug Safe Handling Precautions Other ONS resources: ONS Safe Handling of Hazardous Drugs Quick Guide Introduction to Safe Handling Huddle Card Safe Handling of Hazardous Drugs Learning Library Hematology/Oncology Pharmacy Association (HOPA) course: Safe Handling of Hazardous Drugs National Institute for Occupational Safety and Health (NIOSH) List of Hazardous Drugs in Healthcare Settings, 2024 To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We thought that in order to answer some of the unclear questions about health risk, we would set up an exposure registry, in this case, for oncology personnel who handle the drugs. This would then create a cohort that we could ask questions to. For example, we could try to characterize whether there is a cancer excess in this group. Or characterize the reproductive abnormalities in excess that people are experiencing." TS 6:21 "It's sort of counterintuitive that the healthcare industry, whose mission itself is care of the sick, is a high-hazard industry. We typically think about the risk as being from infectious diseases, and certainly we've all lived in our practice lifetime through some examples of that. Even before COVID-19, some of us were doing preparation for Ebola and that sort of thing. So, we're kind of used to that. But the hazards that you kind of grew up with, we've routinized or normalized handling group one, human carcinogens, which a number of these drugs are—it's just something we do every day. Well, it is, but we have to do it with respect and with care every day. And I think sometimes in that routineness of it, we have sort of lost sight of the vigilance that we need to maintain." TS 11:19 "It's very easy in the life cycle of a drug in an organization to do something that doesn't just impact you, but unknowingly, you've contaminated a surface for somebody who comes behind you. Who maybe doesn't have plastic protective equipment on because something that got contaminated shouldn't have been contaminated in the first place. If we could all be thinking of it as more of a team sport, especially in terms of safe handling, that our disposition and drug handling affects not just us and our health, but those of our colleagues." TS 24:47 "For the job history pieces, we ask what year you started, what year you stopped, and we ask about estimations of handling. So we'll be able to come up with either a duration or some kind of metric for the intensity and duration of your handling history, which will then permit us to sort the population who completed the survey into sort of low, medium, high. And we'll see whether the health outcomes that are being reported are influenced by that drug handling history." TS 27:45 "The idea that we aren't exposed to the same therapeutic dose we give to our patients is absolutely true. However, the dosing schedule to them versus us is very different, and we are exposed frequently, if not daily, to very small concentrations. They don't reach a cytotoxic dose necessarily, but we do know from a lot of studies that either ourselves or our colleagues are taking up drug from contaminated work environments. And you've probably seen there is an awful lot of intermediate evidence looking at genotoxic insult in pharmacists and nurses who handle the drugs. So clearly we're showing uptake and we're showing that there are biologically plausible, concerning measures that are taking place in us. So, I think that we need to come back and circle around the idea that we need to have deep respect for the toxicity of these agents." TS 35:03

Cadillac ep. 810 Shawn Brink (writing under Shawn D. Brink and Shawn David Brink) resides in Eastern Nebraska, U.S.A. and is represented by Liverman Literary Agency. He's building a following with a growing list of novels (mainly speculative fiction), as well as shorter works published in various publications and anthologies. His seventh novel 'The Tunnel Rat' is currently under contract consideration through Tell-Tale Publishing Group. Check out his website to learn more: https://shawnbrinkauthor.wordpress.com/.   ---- Listen Elsewhere ---- YouTube:  https://www.youtube.com/c/TallTaleTV Website: http://www.TallTaleTV.com   ---- Story Submission ---- Got a short story you'd like to submit? Submission guidelines can be found at http://www.TallTaleTV.com   ---- About Tall Tale TV ---- Hi there! My name is Chris Herron and I'm an audiobook narrator. In 2015, I suffered from poor Type 1 diabetes control which lead me to become legally blind for almost a year. The doctors didn't give me much hope, predicting an 80% chance that I would never see again. But I refused to give up and changed my lifestyle drastically. Through sheer willpower (and an amazing eye surgeon) I beat the odds and regained my vision. During that difficult time, I couldn't read or write, which was devastating as they had always been a source of comfort for me since childhood. However, my wife took me to the local library where she read out the titles of audiobooks to me. I selected some of my favorite books, such as the Disc World series, Name of the Wind, Harry Potter, and more, and the audiobooks brought these stories to life in a way I had never experienced before. They helped me through the darkest period of my life and I fell in love with audiobooks. Once I regained my vision, I decided to pursue a career as an audiobook narrator instead of a writer. That's why I created Tall Tale TV, to support aspiring authors in the writing communities that I had grown to love before my ordeal. My goal was to help them promote their work by providing a promotional audio short story that showcases their writing skills to readers. They say the strongest form of advertising is word of mouth, so I offer a platform for readers to share these videos and help spread the word about these talented writers. Please consider sharing these stories with your friends and family to support these amazing authors. Thank you!   ---- legal ---- All stories on Tall Tale TV have been submitted in accordance with the terms of service provided on http://www.talltaletv.com or obtained with permission by the author. All images used on Tall Tale TV are either original or Royalty and Attribution free. Most stock images used are provided by http://www.pixabay.com , https://www.canstockphoto.com/ or created using AI. Image attribution will be declared only when required by the copyright owner. Common Affiliates are: Amazon, Smashwords  

For more thoughts, clips, and updates, follow Avetis Antaplyan on Instagram: ⁠https://www.instagram.com/avetisantaplyanIn this episode of The Tech Leader's Playbook, Avetis Antaplyan sits down with Kurt Uhlir, seasoned CMO, operator, and advisor to private equity-backed growth companies, for a no-BS breakdown of what modern marketing and real leadership look like at scale.Kurt challenges the mainstream playbook with sharp insight into why most CMOs aren't actually marketers, how obsession with attribution is damaging businesses, and why the real differentiator is trust, not clicks. From dismantling the myth of PPC-fueled growth to showing how brands win by building long-term category authority, Kurt shares hard-won lessons from the trenches of B2B SaaS and services.You'll hear how he thinks about short-term vs long-term growth horizons, why servant leadership isn't soft, and what companies miss when they separate marketing from customer success. This is a masterclass for any founder, CMO, or growth leader who wants to scale responsibly, attract vs. chase customers, and build teams that actually own outcomes.If you've ever felt like traditional marketing advice didn't match the reality of scaling a company, this one's for you.TakeawaysMost CMOs are actually salespeople afraid of making cold calls, not strategic marketers.Companies lose 70% of deals by not being one of the top 3 trusted brands in the buyer's mind.Short-term tactics (PPC, partnerships) drive revenue from 2–12 months, but trust drives revenue from 12–36+ months.Modern marketing must focus on contribution to outcomes, not just attribution metrics.Search Everywhere Optimization (not just SEO) is now essential, across YouTube, app stores, LLMs, and social.AI is a force multiplier for small teams, if used correctly to repurpose and amplify valuable content.Great marketing starts by mining product usage data, support tickets, and customer success conversations, not keyword tools.Servant leadership isn't about being soft, it's about owning outcomes and developing people.The best leaders are also great followers, especially when serving a strong brand-driven CEO.The cost of authoritative leadership is silent disengagement and missed opportunities for feedback.If every team member can't explain how their role connects to company outcomes, leadership has failed.The most honest marketing feedback comes from calling customers who canceled, and listening without selling.Chapters00:00 Intro & Kurt's Opening Shot at Modern Marketing02:00 Attribution vs. Contribution05:00 The 70% Rule: Brand Trust and B2B Decision-Making08:00 Should You Aim to Be a Top 3 Brand?10:00 The Three Horizons of Marketing ROI13:00 Search Everywhere Optimization and the New SEO Reality16:30 AI + Content Workflows: From Reels to Repurposing18:30 Content Strategy Starts with Customer Support Data20:00 Servant Leadership vs. Authoritative Leadership24:00 Following When It Matters: The Power of Deference26:00 Communication at Scale: Berkman Assessments and Team Alignment28:00 The Silent Cost of Authoritative Leadership30:00 Attribution Is Easy, But Contribution Builds Companies34:00 Why Marketing Should Own Customer Success Insights36:30 Managing Expectation Risk in Sales vs. Service38:30 Creating a Single View of the Customer40:00 Amplifying Referrals Without Getting in the Way42:00 The Ground Truth Lives With Canceled Customers43:30 Atomic Habits, Sticker Charts, and Showing Up44:30 The Billboard Test for Great Leadership Kurt Uhlir's Social Media Link:https://www.linkedin.com/in/kurtuhlir/Kurt Uhlir's Website Link:https://kurtuhlir.com/Resources and Links:⁠https://www.hireclout.com⁠⁠https://www.podcast.hireclout.com⁠⁠https://www.linkedin.com/in/hirefasthireright

It's almost time for the Oscar noms! Hosts Ema Sasic and Kevin Schwaller go through their nominees in a number of categories. What do you think of their picks? Will they be entirely wrong? We'll find out on Thursday.Disclaimer:Copyright notice:(Intro/outro) She's The Greatest Dancer by Ryan Andersen is licensed under a Attribution-NonCommercial License. https://freemusicarchive.org/music/Ryan_Andersen/MORE/Shes_The_Greatest_Dancer?fbclid=IwAR1TDCO9eT6TxmDrTaJr9HRQVk2gUu00cNXeG8oik3avXVEhbSGqsqUfLkoCopyright notice:(Break) Extremely Tik-tok compatible for slow videos by Lundstroem is licensed under a Attribution 4.0 International License. https://freemusicarchive.org/music/lundstroem/the-happiest-songs/extremely-tik-tok-compatible-for-slow-videos/

The party attempts a terrifying ruse to gain access to the Cradle of Lamashtu.WebsiteDiscordTwitterPathfinder Second Edition and the Kingmaker Adventure Path are published by Paizo."Take the Lead" and other featured music were composed by Kevin MacLeod and licensed under Creative Commons by: Attribution 4.0 License.All ambiances were composed by Michael Ghelfi Studios.The Zero Check are committed to providing an inclusive and respectful experience to all listeners, but we also recognize and acknowledge that we are limited by our individual frames of reference. If we misstep, please let us know. Email all feedback to feedback@zerocheckpodcast.com.Thank you for listening to The Zero Check. Send us a text

My guest today is Brian Bauer from Bauer Entertainment Marketing.  We had a great marketing conversation that I think you are going to learn a ton from.  In today's conversation, we talk about: 1 to 1 marketing Attribution Zero click searches Brand awareness Marketing investments And, just tons more.  A great marketing conversation.  Check out my website at www.DaveWakeman.com Get the 'Talking Tickets' newsletter at https://talkingtickets.substack.com Join our Slack Channel here! 

"[Multiple myeloma] is very treatable, very manageable, but right now it is still considered an incurable disease. So, patients are on this journey with myeloma for the long term. It's very important for us to realize that during their journey, we will see them repeatedly. They are going to be part of our work family. They will be with us for a while. I think it's our job to be their advocate. To be really focused on not just the disease, but periodically assessing that financial burden and psychosocial aspect," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 16, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the pathophysiology and diagnosis of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 332: Best Nursing Practices for Pain Management in Patients With Cancer Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 192: Oncologic Emergencies 101: Hypercalcemia of Malignancy ONS Voice articles: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications Cancer Mortality Declines Among Black Patients but Remains Disproportionately High Financial Navigation During Hematologic Cancer Saves Patients and Caregivers $2,500 Multiple Myeloma: Detecting Genetic Changes Through Bone Marrow Biopsy and the Influence on Care Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment Diagnose and Treat Hypercalcemia of Malignancy ONS books: BMTCN® Certification Review Manual (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing articles: African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities Music Intervention: Nonpharmacologic Method to Reduce Pain and Anxiety in Adult Patients Undergoing Bone Marrow Procedures Other ONS resources: Financial Toxicity Huddle Card Hypercalcemia of Malignancy Huddle Card Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Cancer Society article: What Is Multiple Myeloma? Blood Cancer United educational resources page International Myeloma Foundation homepage Myeloma University homepage Multiple Myeloma Research Foundation (MMRF) article: Understanding Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Epidemiologically, myeloma is a cancer of older adults. The median age is about 69. It is more common in men than women. It's a ratio of about three men to two women that are diagnosed. It is much more common in people of African American descent with increasing global incidence linked to aging populations. Although, the highest rates are in high-income countries. So, if we look at some of the risk factors, and several have been identified, including MGUS. MGUS is a benign precursor of myeloma, and it stands for monoclonal gammopathy of undetermined significance. Older age is also a risk factor, although we do see patients that are younger who are diagnosed with myeloma." TS 1:54 "Bone pain, specifically in the back, and fatigue, are very common symptoms that relate to things that are going on behind the scenes with myeloma. But also, patients can be bothered by frequent and long-lasting infections. So, they find that they get sick more frequently than their family and friends, and they take a longer time to recover. That could also be a presenting sign. I think there can be some presenting signs and symptoms related to electrolyte abnormalities, especially in later stages. They might be nauseated, vomiting, or constipated. Also, signs and symptoms related to cytopenias. You have to remember that this is a bone marrow cancer. So, we do have some problem with development of normal blood cells. So, we can see not only infections, but bleeding issues related to thrombocytopenia and factors related to anemia from low red blood cell counts." TS 7:15 "About 20%–25% of our patients who are diagnosed are asymptomatic. They have no symptoms. They're living their lives, they're going to work or they're traveling, playing golf on the weekends, taking care of their children or grandchildren. They are just living their lives. And at times, they go to the primary care physician and then they're referred to a hematologist-oncologist, and they're pretty surprised when they're sent to a cancer center. The way they are diagnosed in this matter is that their routine lab work, the complete blood cell count may be normal, there may be some slight differences in their hemoglobin. But what we see in the chemistry, the complete metabolic panel, is an elevation in their total protein and or an elevation of the total globulins." TS 9:22 "The bone marrow biopsy serves many purposes. You want to determine the percentage of bone marrow plasma cells. So, you want to get the degree of plasmacytosis. And then you want to do really specific tests on those plasma cells. So, you want to isolate the malignant plasma cells and determine, via analysis. So, we do the karyotype, chromosomal studies, fluorescence in situ hybridization (FISH) studies, immunohistochemistry studies, and molecular studies. All of these studies are looking for specific genetic changes in the myeloma cells—looking for translocations or deletions. And it's very important to get that information because we can put patients in a category of having standard-risk disease versus high-risk disease. And that can give us a better picture of what this patient's journey with myeloma may look like." TS 13:41 "When I used to work in lymphoma, I spoke with the physicians who were lymphoma specialists, and they said that they foresee a future in having these assays that detect circulating tumor cells actually take the place of imaging studies like restaging positron-emission tomography (PET), computed tomography (CT) scans. So, it's really amazing, these tests that are on the market now and maybe not as widespread as we'd like, but there's a lot of nice assays out there that will become more popular and used more commonplace in the future that I think are going to help identify myeloma more precisely. ... If you think about myeloma, even with measurable residual disease (MRD), MRD for leukemia, for lymphoma, you take a blood sample, you test it for MRD. For myeloma, you need a bone marrow biopsy. You need a bone marrow sample. You can't do MRD on a blood sample for myeloma. Not yet. But if we perfect these assays and we can eventually detect this, then you're looking at a whole new ballgame. You can even perfect your MRD testing as well. So, it's a very exciting time for some of these heme malignancies." TS 28:09

Hosts Kevin Schwaller and Ema Sasic continue to attempt to survive this awards season with a recap of the Golden Globes, as well as some SAG Actor Awards nominations and predictions. Buckle up because there's *checks notes* about two months to go! Who are you rooting for? Do you like the SAG name change?Disclaimer:Copyright notice:(Intro/outro) She's The Greatest Dancer by Ryan Andersen is licensed under a Attribution-NonCommercial License. https://freemusicarchive.org/music/Ryan_Andersen/MORE/Shes_The_Greatest_Dancer?fbclid=IwAR1TDCO9eT6TxmDrTaJr9HRQVk2gUu00cNXeG8oik3avXVEhbSGqsqUfLkoCopyright notice:(Break) Extremely Tik-tok compatible for slow videos by Lundstroem is licensed under a Attribution 4.0 International License. https://freemusicarchive.org/music/lundstroem/the-happiest-songs/extremely-tik-tok-compatible-for-slow-videos/

Okay. This show today is part of our Relentless Health Value "The Inches Are All Around Us" series. This Inches Talk is a metaphor for finding all those little places where there is healthcare waste as a first step in an effort to excise all these little pockets of waste. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. Shane Cerone said this phrase during episode 492, and I loved it because there are inches all around us for sure. And the thing with all these inches that we're gonna talk about today and last week and next week and the week after that, yeah, these are inches that actually you could cut them. And there are millions and billions of dollars, and you actually improve patient care. You improve clinical team experience. Also, you're cutting out friction and making it easier to do the right thing to care for patients. These are no-brainer kinds of stuff if your North Star is better and more affordable patient care, but they are also somebody else's bread and butter in a "one person's cost is another person's revenue" kind of way. So, yeah … what makes perfect common sense might not be as easy as it might look on paper, as we all know so well. So, last week we dug into all of the inches of expensive friction that develop when stakeholders interact—like, a clinical organization and a payer and a plan sponsor, self-insured employer. They try to get paid or pay. They try to direct contract because what will be found fast enough is that the data is not the data is not the data, as Mark Newman talked about last week (EP496); and a dollar is not a dollar is not a dollar. Again, you'll find this out fast enough. All of you know when you talk to entities up and down the patient journey or across the life of a claim, otherwise known as a healthcare transaction. It's mayhem to get a claim paid often enough. Each stakeholder comes in with their own priorities and views and accounting methods and various rollups. I like how Stephanie Hartline put it. She wrote, "Healthcare … moves through many hands without a rail that preserves truth along the way. Attribution breaks, and truth gets reassembled later. The difference isn't capability—it's infrastructure. Line-item billing ≠ line-item settlement." Or I also like how Chris Erwin put it. He wrote, "When the blueprint isn't standardized, you aren't scaling. You're just compounding chaos." And yeah, then all of a sudden when there's no through line, there's no rail that connects all the data to the data to the data, or all the dollars to the dollars to the dollars. Suddenly 30% of any given healthcare transaction goes to trying to straighten it all back out again—to reassemble it, as Stephanie said. It's like unleashing 100 chaos monkeys and then having to pay to recapture them all. Listen to the show with David Scheinker, PhD (EP363) from last year about "Hey, how about we all just use the same template and avoid a lot of this." Or read Zeke Emanuel's book about how the USA should potentially consider copying the Netherlands model because they have private insurance. But they cut admin costs 75% or something like that. Oh, right … through standardization. Jesse Hendon summarized this the other day. He wrote, "Providers don't need armies of coders to fight 50 different insurance rule books [when you have some standardization here]." I say all this to say after recording the episode with Mark Newman from last week, I have become intently fascinated by what goes on in this non-standardized or otherwise friction points between stakeholders. There are a lot of inches in this gray area land of confusion.   This show today digs into one of them, which is what does it take to process a claim? Just technically. What are the pipes involved to submit a claim and, again, get paid for it, which is a healthcare transaction—just simply the technology moving the data around—even if everything in the pipes is a non-standardized hot mess. Because just fixing up the processing and the pipes here—again, while this doesn't solve the entire data isn't a data isn't a data or a dollar isn't a dollar isn't a dollar problem—if we can just cut out some of the processing and the moving the data around costs, just this all by itself is $6 billion a year worth of inches. Plus, as an added bonus, fix up the pipes for better data flow and now patient care can be faster if, for example, the prior auth or etc. processes transpire faster. And clearinghouses have entered the chat. But you know, when clearinghouses come up, at least in my world, when the clearinghouse word gets dropped, it's usually accompanied by like a puff of smoke because no one is quite sure what those guys do all day. So, we all sort of look at each other in the conversation and move on. Lucky for me and possibly you if I've managed to suck you into my web of intrigue, I ran into Zack Kanter from Stedi, a new clearinghouse, who agreed to come on the pod here and aid my exploration into this demarcation zone between stakeholders. So, let's start here. What is a clearinghouse? Well, a clearinghouse is the same thing as a switch when we're talking about pharmacy data transfers, if you're familiar with that terminology and that's helpful. But either way, in the conversation with Zack Kanter that follows, Zack will explain this better; but clearinghouses are like a hub, maybe, that connects all the payers with all the providers. So, if you want an eligibility check or you wanna submit a claim or do a prior auth of the payer, whatever you're trying to do, get paid, you as an EHR system or a doctor's office or an RCM (revenue cycle management) company, you don't have to set up your own personal data connection with every single payer out there. You don't have to go through all the authentications and the BAAs (Business Associate Agreements) and map all the fields and set up the 100 SOC 2–compliant APIs (application programming interfaces). Instead, you can hook up to one clearinghouse, and then that clearinghouse connects with everybody else. So, most medical claims transactions have a clearinghouse in the middle, like an old-timey telephone operator routing your claim or denial or approval of that claim or eligibility check or whatever to the right place. And unfortunately, old-timey telephone operator is a pretty apt metaphor, depending on which clearinghouse you're using. Anyway, Zack Kanter told me that the price to just send and receive an electronic little piece of data in healthcare through a clearinghouse costs about 1,000 times more than any other industry would pay. Like, if you do an eligibility check, that's gonna cost 10 to 15 cents per. The trucking industry pays that much for 1,000 such data transfers. They would riot if someone asked them to spend a dollar for 10 data transfers. That'd be ridiculous in their eyes. But in healthcare, all these dimes add up to, again, $6 billion a year—them's some inches there—which also equal delays in payment and patient care. Now you might be thinking, "Oh, well, maybe it costs this much because healthcare is so much more complicated than trucking or whatever." Well, turns out the opposite is true: Because of HIPAA, ironically enough, healthcare is, in fact, much more standardized (we were talking about standardization before); but healthcare is actually much more standardized than many other industries due to HIPAA's administrative simplification rules, which mandate a universal language for transactions—the pipes I'm talking about now. So, actually, for as much as I was just kvetching about chaos monkeys, compared to other industries, the baseline construct here is actually much more orderly than, for example, the trucking industry or whatever, like Amazon or Walmart has to deal with with their millions of vendors. Now—and here's a really big point, especially for self-insured employers—you know who the main customer is for a lot of the more programmatic, the newer kinds of clearinghouses? I'll tell you: newer digital entities who do RCM (revenue cycle management) for provider organizations, and that can be great if you're a practice just trying to keep up with payer denials and expedite patient care. But look, all you plan sponsors and self-assured employers and maybe unions out there, the more RCM purveyors start working with programmatic clearinghouses, the more you not doing programmatic prepayment integrity programs with unconflicted third-party prepayment integrity vendors who are as hooked into the data streams and the clearinghouses as the RCM vendors are, the more, as I said last week, increasingly you're bringing an ever more rusty knife to a gunfight. So, that is certainly something to consider. There's a whole episode next week about this with Mark Noel from ClaimInsight. Or if you just can't wait, go back and listen to the show with Kimberly Carleson (EP480) just for the gist of it, or the one with Dawn Cornelis (EP285) from a few years ago. They're talking post-payment integrity programs, but a lot of the same rules apply. The show today is sponsored by Aventria Health Group, as usual. But I do want to say that we got some very appreciated financial support from Stedi, the only programmable healthcare clearinghouse. And here is my conversation about all of the inches that are all around us, specifically in the healthcare data pipes, with Zack Kanter, who is the CEO and founder over at Stedi. Also mentioned in this episode are Stedi; Shane Cerone; Mark Newman; Stephanie Hartline; Chris Erwin; David Scheinker, PhD; Zeke Emanuel, MD, PhD; Jesse Hendon; Mark Noel; ClaimInsight; Kimberly Carleson; Dawn Cornelis; Aventria Health Group; Preston Alexander; Eric Bricker, MD; and Kada Health. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at stedi.com. You can also follow Zack and Stedi on LinkedIn.   Zack Kanter is the founder and CEO of Stedi, the only programmable healthcare clearinghouse. Stedi has raised $92 million from Stripe, Addition, First Round, USV, Bloomberg Beta, and other top investors. He has previously appeared on podcasts, including In Depth by First Round Capital, Invest Like the Best, Village Global, and Rule Breaker Investing.   09:47 What things are being paid for that we might not be aware we're paying for in healthcare? 12:09 Why HIPAA actually makes healthcare more standardized than other industries. 15:35 How healthcare is ahead in some ways and behind in others. 18:03 Where do the 4 to 5 days come from in healthcare transaction processing? 20:39 Why these transaction delays affect care delay. 23:14 EP482 with Preston Alexander. 23:18 EP472 with Eric Bricker, MD. 27:10 How should the process work from the time a provider clicks "validate"? 30:19 Why is the clearinghouse the right place to solve all these issues? 31:41 Why are we where we are in terms of these issues? 35:28 Why people should be looking at their clearinghouse costs. 36:59 What to know about Stedi.   You can learn more at stedi.com. You can also follow Zack and Stedi on LinkedIn.   @zackkanter discusses #healthcaretransactions and #clearinghouses on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Mark Newman, Stacey Richter (INBW45), Stacey Richter (INBW44), Marilyn Bartlett (Encore! EP450), Dr Mick Connors, Sarah Emond (EP494), Sarah Emond (Bonus Episode), Stacey Richter (INBW43), Olivia Ross (Take Two: EP240)

Attribution has always been a challenge for marketers, and today's internet only makes it harder. Cookie banners frustrate users, bots distort signals, and brands face growing liability for the data they collect. What if there were a way to fix all of this while giving individuals true ownership of their online identities? In this episode, Gabriella Mirabelli speaks with Patrick Moynihan, co-founder and president of Tracer Labs, about Trust ID, a portable, user-owned digital identity built on blockchain technology. Trust ID enables consumers to control consent on a site-by-site basis, reduces friction in online experiences, and provides a digital wallet for secure transactions. For brands, it offers cleaner CRM data, stronger attribution, and less exposure to privacy risks. Patrick shares how the concept evolved from a referral-tracking tool into a potential new standard for digital trust, why adoption is easier than many assume, and what the future might look like if individuals—not platforms—hold the keys to their own data.

We dig into why traffic is fragmenting, why single-channel expertise won't cut it, and how expert generalists, stronger offers, and brand strategy are now the true growth levers. We share a practical path from productized “done-for-you” to higher-margin “done-with-you,” plus frameworks for attribution, remote team performance, and human-in-the-loop AI.• AI-driven traffic shifts and platform changes• Generalists with deep skills as the new edge• Offers, positioning, and CRO over channel tricks• Human-in-the-loop standards to avoid AI slop• Done-with-you consulting to expand TAM and margin• Retainers, value pricing, and capacity planning• Attribution redesign and qualification signals• Objectives, metrics, KPIs, and NPS for retentionGuest Contact Information: Website: agencyacquisitions.ioLinkedIn: linkedin.com/in/nickavariaTwitter/X: x.com/Nick_AvariaYouTube: youtube.com/@AgencyAcquisitionsInstagram: instagram.com/nick_avariaMore from EWR and Matthew:Leave us a review wherever you listen: Spotify, Apple Podcasts, or Amazon PodcastFree SEO Consultation: www.ewrdigital.com/discovery-callWith over 5 million downloads, The Best SEO Podcast has been the go-to show for digital marketers, business owners, and entrepreneurs wanting real-world strategies to grow online. Now, host Matthew Bertram — creator of LLM Visibility™ and the LLM Visibility Stack™, and Lead Strategist at EWR Digital — takes the conversation beyond traditional SEO into the AI era of discoverability. Each week, Matthew dives into the tactics, frameworks, and insights that matter most in a world where search engines, large language models, and answer engines are reshaping how people find, trust, and choose businesses. From SEO and AI-driven marketing to executive-level growth strategy, you'll hear expert interviews, deep-dive discussions, and actionable strategies to help you stay ahead of the curve. Find more episodes here: youtube.com/@BestSEOPodcastbestseopodcast.combestseopodcast.buzzsprout.comFollow us on:Facebook: @bestseopodcastInstagram: @thebestseopodcastTiktok: @bestseopodcastLinkedIn: @bestseopodcastConnect With Matthew Bertram: Website: www.matthewbertram.comInstagram: @matt_bertram_liveLinkedIn: @mattbertramlivePowered by: ewrdigital.comSupport the show

The party travels to the Cradle of Lamashtu to confront the cult responsible for the Curse of the Bloom.WebsiteDiscordTwitterPathfinder Second Edition and the Kingmaker Adventure Path are published by Paizo."Take the Lead" and other featured music were composed by Kevin MacLeod and licensed under Creative Commons by: Attribution 4.0 License.All ambiances were composed by Michael Ghelfi Studios.The Zero Check are committed to providing an inclusive and respectful experience to all listeners, but we also recognize and acknowledge that we are limited by our individual frames of reference. If we misstep, please let us know. Email all feedback to feedback@zerocheckpodcast.com.Thank you for listening to The Zero Check. Send us a text

In June of 2007, police in Portage, WI were following-up on a tip regarding a missing persons case from Florida, when they found a literal "House of Horrors" in a local rental property.  The sheer amount of abuse and torture, ultimately culminating in murder, created headlines nationwide, and led to numerous states reviewing and ovverhauling state laws in regards to foster care and oversite. Although bodies buried in the back yard and tortured children locked in closets sounds like fodder for horror films, this was realty for a house in Portage. The investigation which unfolded, uncovered a ring of identity thieves, causing havoc and ruining lives in many states throughout the country.  Scott and Mickey discuss this case, what enabled it, and its aftermath, including some of the misteps that were taken, repeatedly, by people in positions meant to help avoid these crimes ocurring in the first place.  In the opening banter we discuss a similar case in Outagamie County currently being adjudicated, tie up the Morgan Geyeser saga, and further evidence of why WI remains a UFO hotbed.  All here, on Episode 60 of Badger Bizarre, "Portage House of Horrors."   Facebook Twitter Website Email us:  badgerbizarre@outlook.com   Opening Trailer: Ed Gein Sound Byte : "Hard Copy" - Paramount Domestic/CBS Televsion Frank Lloyd Wright and Jeffery Dahmer Sound Byte - WISN 12 News - Milwaukee, WI Jeffery Dahmer Quotes: "Inside Edition"  - King World/CBS Television/CBS Media   Attribution for Music: Trailer: Composer: Adam Phillip Zwirchmayr https://www.pond5.com/ Intro: https://pixabay.com/ Outro: Composer: Viacheslav Sarancha  https://www.pond5.com/   Attribution for logo design: Red Claw Scratch Photo   Sources:    Baraboo News Republic - Archives Milwuakee Magazine: "House of Horrors" 3/2008 US Sun - Oshkosh UFO Portage Daily Register - Archives Tampa Bay Times - Archives   Please be sure to visit our Sponsor!  FrameMakers                

2:29 – It’s a song about a hockey team, right? Yeah, that’s the ticket. Words are by Dave in Kentucky, music and show art by Suno.ai (v4.5). License for this track: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) Attribution: by Dave in Kentucky and Suno.ai (v4.5). No further info is available.

Has Iran experienced more foreign interventions than other countries? What really happened to Iran in 1953? And why are Iranians reinterpreting its history now?

"Referring patients to audiology early on has shown dramatic reduction in hearing loss or complications because the audiologist can really see where were they at before they started chemotherapy, where were they at during, if they get an audiogram during their treatment. And then after treatment, it's really important for them to see an audiologist because this is really a survivorship journey for them. And as nurses, the 'so what': We are the first line of defense," ONS member Jennessa Rooker, PhD, RN, OCN®, director of nursing excellence at the Tampa General Hospital Cancer Institute in Florida, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ototoxicity in cancer care. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 9, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of ototoxicity after chemotherapy treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Cancer Symptom Management Basics series ONS Voice articles: Oncology Drug Reference Sheet: Cisplatin Oncology Drug Reference Sheet: Carboplatin Oncology Drug Reference Sheet: Oxaliplatin FDA Approves Sodium Thiosulfate for Cisplatin-Associated Ototoxicity in Pediatric Patients ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition) American Cancer Society resources: 4 Causes of Hearing Problems for Cancer Survivors Cancer Survivors Network American Speech-Language-Hearing Association (ASHA) Hearing Loss: An Under-Recognized Side Effect of Cancer Treatment Embedded Ear Care: Audiology on the Cancer Treatment Team American Society of Clinical Oncology (ASCO) Annual Meeting abstract: Innovative Infusion Center Assessments of Chemotherapy-Induced Neurotoxicities: A Pilot Study Supporting Early and Routine Screenings as Part of Survivorship Programs Children's Oncology Group supportive care endorsed guideline: Prevention of Cisplatin-Induced Ototoxicity in Children and Adolescents With Cancer: A Clinical Practice Guideline Ear and Hearing article: Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment International Ototoxicity Management Group (IOMG) IOMG Wikiversity page Shoebox hearing assessments World Health Organization initiative: Make Listening Safe To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "At different pitches, the eardrums move faster or slower, signaling the inner ear, or the cochlea—the thing that looks like a snail in the pictures. The cochlea has fluid and hair cells inside of it that receive movements from the eardrum. The hair cells change the movement into electrical signals that actually go to the auditory nerves or the cranial nerve VIII." TS 2:15 "Ototoxicity is an umbrella term for some sort of exposure to a toxin that causes damage to the inner ear. These toxins can be in the environment, such as loud or different noises, or they can be from medications, including antibiotics or commonly cancer treatments, such as radiation chemotherapy. Some common chemotherapies can be platinum-based chemotherapies like cisplatin or carboplatin. And then what patients are experiencing if they have ototoxicity can be hearing loss." TS 3:15 "The hypothesized mechanism of action is that the chemicals like the platinum compound in cisplatin … that platinum compound travels through our bloodstream. Since chemotherapy is systemic, it'll go to the inner ear, and it gets stuck there by binding to the cellular DNA in that cochlea, or that snail-looking image. That initiates the release of the reactive oxygen species, which are really trying to help clean it out, but releases such high levels that it ends up causing damage to those inner ear hairs. These inner ear hairs cannot regenerate themselves, so then they're permanently damaged. And remember we said that those hairs send electrical signals to the brain that recognize sound. So that function is permanently gone once those hair cells are damaged." TS 7:10 "I definitely think this is a huge interdisciplinary collaborative effort. As nurses and advanced providers, we're assessing and providing education. Our medical oncologists are doing those dose modifications and submitting those audiology referrals. The radiation oncologists are very important to know about this—maybe dose localization awareness. Maybe they do some changes with the doses. And then our audiologists and [ear, nose, and throat physicians], they can do that diagnostic confirmation and any rehabilitation measurements and really monitor them throughout their journey as well. And nurse navigators play a huge part in making sure those patients get those referrals, because a lot of the time the audiologists aren't in the cancer clinic, so they may have to go to another location or may need help coordinating with all their appointments that they have." TS 22:28 "We had a really innovative way of monitoring the hearing that a couple other studies have also tested. It's a remote point-of-care hearing screen. It was on [a tablet] with calibrated headphones. And then it's a paid-for subscription to an audiology testing platform. … Myself, along with a couple of other nurses, were trained how to use this testing device with the tablet and the headphones and the software program. And it was a quick down-and-dirty portable hearing assessment for patients. So anyone who was new to cisplatin, never gotten cisplatin treatment before, was enrolled into the study, and they received a hearing test every time that they came for chemo, and we gave it to them during their hydration." TS 28:59  

We're in the middle of award season so get ready, everyone! Hosts Ema Sasic and Kevin Schwaller recap the Critics Choice Awards winners and predict who they think will win at the Golden Globes on Sunday. Disclaimer:Copyright notice:(Intro/outro) She's The Greatest Dancer by Ryan Andersen is licensed under a Attribution-NonCommercial License. https://freemusicarchive.org/music/Ryan_Andersen/MORE/Shes_The_Greatest_Dancer?fbclid=IwAR1TDCO9eT6TxmDrTaJr9HRQVk2gUu00cNXeG8oik3avXVEhbSGqsqUfLkoCopyright notice:(Break) Extremely Tik-tok compatible for slow videos by Lundstroem is licensed under a Attribution 4.0 International License. https://freemusicarchive.org/music/lundstroem/the-happiest-songs/extremely-tik-tok-compatible-for-slow-videos/

Nesse podcast conversamos com Tatiana Wisniewski, que é gerente ou coordenadora de pós-produção em Hollywood, tendo trabalhado em filmes como Gran Turismo (2023), Will e Harper (2024) e Eleanor a Grande (2025), a estreia de Scarlett Johansson na direção. Falamos sobre quais as atribuições da pós-produção, como é trabalhar no mercado estadunidense e as expectativas em tempos de monopólios. O programa é apresentado por Isabel Wittmann.Feed | Bluesky | Instagram | Letterboxd | TelegramPesquisa, roteiro, apresentação, produção, edição e capa: Isabel Wittmann Vinheta: Felipe Ayres Locução da vinheta: Deborah Garcia (deh.gbf@gmail.com)Música de encerramento: Bad Ideas - Silent Film Dark de Kevin MacLeod está licenciada sob uma licença Creative Commons, Attribution, Origem, Artista.Apoie nosso financiamento coletivo: https://feitoporelas.com.br/apoie/ ou pix contato@feitoporelas.com.br

Mitch Skatter joins the show this week to recap his 2025 pheasant season, chat about Pheasant Fest 2026, and take a deep dive on his Garmin dog GPS questions. Check out Mitch's YouTube Channel, Upland Path for more of his tips and tricks for bird hunting: https://www.youtube.com/@UplandPathThis episode is brought to you by Ugly Dog Hunting Co. Shop now at UglyDogHunting.comMusic used under Creative Commons -Two Step Daisy Duke by Mr. Smith is licensed under an Attribution 4.0 International License.

Send us a textWhat if every dollar spent on ads could be traced to a signed contract, a booked meeting, or a new client? The disconnect between ad spend and revenue isn't a mystery businesses have to live with. This problem, the attribution gap, can be solved through methodical thinking, technical capability, and a willingness to build the infrastructure that connects marketing activities to real business outcomes. In this episode, we pull back the curtain on two concrete case studies using two real companies who faced the maddening reality: their CRM systems and ad platforms weren't talking to each other. Tune in to see how Optidge built the data bridges that transformed guesswork to strategic growth and implemented deliberate optimization tactics across their ad campaigns to drive further success.  An Optidge "Office Hours" Episode:Our Office Hours episodes are your go-to for details, how-to's, and advice on specific marketing topics. Join our fellow Optidge team members, partners, and sometimes even 1:1 teachings from Danny himself, in these shorter, marketing-focused episodes. Get ready to get marketing!Episode Highlights: Marketing attribution requires connecting ad platforms to revenue data, not just lead counts.Building a feedback loop between CRM and advertising platforms transforms how you optimize campaigns.Data silos prevent businesses from understanding which marketing efforts drive actual revenue.Custom attribution pipelines can reveal sales cycles, funnel speed, and high-value customer sources.Fragmented tech stacks create blind spots that make it impossible to track leads to final conversions.Episode Links: OptidgeOptidge Services: Hubspot for Paid MediaPaid Search Association Webinar: Hubspot and Google Ads - Everything You Wanted to KnowThe DM Mentor on InstagramFollow The Digital Marketing Mentor: Website and Blog: thedmmentor.com Instagram: @thedmmentor Linkedin: @thedmmentor YouTube: @thedmmentor Interested in Digital Marketing Services, Careers, or Courses? Check out more from the TDMM Family: Optidge.com - Full Service Digital Marketing Agency specializing in SEO, PPC, Paid Social, and Lead Generation efforts for established B2C and B2B businesses and organizations. ODEOacademy.com - Digital Marketing online education and course platform. ODEO gives you solid digital marketing knowledge to launch/boost your career or understand your business's digital marketing strategy.

Find Merch here: https://theirrelevant.org/store Join The El Pochcast Discord here: https://discord.gg/AS8RuMHsxJ Bluesky: @elpochcast.pocho.online Instagram: @elpochcast Email : elpochcast@ gmail.com Text: www.pocho.online El Pochcast is a part of The Irrelevant Podcast Network rapture.mp3 by Vincent Augustus is licensed under a Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/ Support El Pochcast by contributing to their tip jar: https://tips.pinecast.com/jar/el-pochcast

In the latest episode of The World of Marketing, Tom Foster sits down with Eiman Bassam, Founder & CEO of ESB Advertising, to break down how streaming TV advertising has evolved—and why lawyers and doctors can no longer afford to treat TV as a "branding-only" channel. This conversation challenges one of the biggest assumptions in marketing: that TV can't be measured. In this episode, you'll learn: Why programmatic streaming TV is now more measurable than traditional broadcast How ESB's AI platform, MACData, tracks performance down to the household level What actually drives ROI beyond cheap CPMs How AI is reshaping media buying, attribution, and even commercial creation Why "How did you hear about us?" is officially outdated If you've ever questioned whether streaming TV advertising really works - or struggled to connect ad spend to real revenue - this is a conversation worth your time.

The party returns to Fort Trand to conduct the kingdom's business and investigate the newly discovered Cradle of Lamashtu.WebsiteDiscordTwitterPathfinder Second Edition and the Kingmaker Adventure Path are published by Paizo."Take the Lead" and other featured music were composed by Kevin MacLeod and licensed under Creative Commons by: Attribution 4.0 License.All ambiances were composed by Michael Ghelfi Studios.The Zero Check are committed to providing an inclusive and respectful experience to all listeners, but we also recognize and acknowledge that we are limited by our individual frames of reference. If we misstep, please let us know. Email all feedback to feedback@zerocheckpodcast.com.Thank you for listening to The Zero Check. Send us a text

"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes  Complete this evaluation for free NCPD. ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting Episode 145: Administer Taxane Chemotherapies With Confidence Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments ONS Voice articles: Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS courses: Complications of Vascular Access Devices (VAD) and IV Therapy ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS Oncology Treatment Modalities Clinical Journal of Oncology Nursing articles: Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review ONS huddle cards: Antineoplastic Administration Chemotherapy Immunotherapy Implanted Venous Port ONS position statements: Administration (Infusion and Injection) of Antineoplastic Therapies in the Home Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies ONS Guidelines™ for Extravasation Management ONS Oncologic Emergencies Learning Library ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The focus of this guideline was specifically on intravenous antineoplastic extravasation or when a vesicant or an irritant with vesicant properties leaks out of the vascular space. This can cause an injury to the patient that's influenced by several factors including the specific drug that was involved in the extravasation, whether it was DNA binding, how much extravasated, the affected area, and individual patient characteristics." TS 1:48 "The panel identified and ranked outcomes that mattered most with extravasation. Not surprising, one of the first was tissue necrosis. Like, 'How are we going to prevent tissue necrosis and preserve tissue?' The next were pain, quality of life, delays in cancer treatment: How is an extravasation going to delay cancer treatment that's vital to the patient? Is an extravasation also going to result in hospitalization or additional surgical interventions that would be burdensome to the patient? ... We had a systematic review team that then went in and summarized the data, and the panel applied the grading of recommendations, assessment, development, and evaluation (GRADE) criteria, grading quality of evidence and weighing factors like patient preferences, cost, and feasibility of an intervention. From there, they developed their recommendations." TS 7:35 "The panel, from the onset, wanted to make sure we had something visual for our readers to reference. They combined evidence from the systematic review, other scholarly sources, and their real-world clinical experience to make this one-page supplementary algorithm. They wanted it to be comprehensive and easy to follow, and they included not only those acute management steps but also guidance on 'How do I document this and what are the objective and subjective assessment factors to look at? What am I going to tell the patient?' In practice, for use of that, I would compare it to your current processes and identify any gaps to inform policies in your individual organizations." TS 16:34 "The guidelines don't take place of clinician expertise; they're not intended to cover every situation, but a situation that keeps coming up that we should talk about as a limitation, is we're seeing these case reports of tissue injury with antibody–drug conjugate extravasation. There's still not enough evidence to inform care around the use of antidotes with those agents, so this still needs to be addressed on a case-by-case basis. We still need publication of those case studies, what was done, and outcomes to help inform direction." TS 19:24 "Beyond the acute management is to ensure thorough documentation regarding extravasation. Whether you're on electronic documentation or on paper, are the prompts there for the nurse to capture all of the factors that should be captured regarding that extravasation? The size, the measurement, the patient's complaints. Is there redness? Things like that. And then within the teams, everyone should know where to find that initial extravasation assessment so that later on, if they're in a different clinic, they have something to go by to see how the extravasation is healing or progressing. ... I think there's an importance here, too, to our novice oncology nurses and their preceptors. This could be anxiety-provoking for the whole team and the patient, so we want to increase confidence in management. So, I think using these resources for onboarding novice oncology nurses is important." TS 22:34

In this episode of "The Free Lawyer," host Gary interviews Bo Royal, a former Fortune 500 marketing executive who successfully transitioned to legal marketing. Bo shares how he quadrupled online case volume at a major Philadelphia injury law firm by implementing data-driven strategies and shifting focus from traditional to digital channels. He discusses the importance of tracking, intake systems, and operational readiness for law firms, and explains how his company, Pareto Legal, helps firms build robust case pipelines. The episode offers practical insights for maximizing marketing efficiency and leveraging digital tools to drive sustainable law firm growth.Bo Royal is a former Fortune 500 agency exec who spent over a decade scaling online revenues for iconic brands like Calvin Klein, GNC, Sallie Mae, and Kate Spade New York. After leaving the corporate grind, he took the helm at a top Philadelphia injury law firm, supercharging its online case volume by fourfold through data-driven decisions and relentless focus. His journey from high-stakes agency work to legal marketing quickly established him as an industry expert with a knack for results.Now, as an advisory board member at that very firm—thriving with eight-figure revenues and 12 office locations across Pennsylvania—Bo drives innovation at Pareto Legal. His team empowers small and medium-sized law firms to secure seven- to eight-figure case pipelines by leveraging real-world experience and smart digital strategies. When he's not optimizing campaigns, Bo shares his marketing insights on podcasts and uses his success to give back to the community.Bo's Transition from Corporate to Legal Marketing (00:02:05) Initial Surprises in Legal Marketing (00:03:59) Diagnosing and Transforming the Law Firm's Marketing (00:05:49) Shifting from Traditional to Digital Marketing (00:08:35)Earned vs. Unearned Case Pipeline (00:10:41) OTT and Modern Advertising Explained (00:12:13) Importance of Data-Driven Decision Making (00:13:19)Implementing a Culture of Data and Change (00:15:45) Pareto Legal's Differentiated Approach (00:18:22) Assessing Firm Readiness for Digital Marketing (00:22:06) Vanity Metrics vs. Real Results (00:25:39) Holistic Marketing Efficiency and Attribution (00:27:52) The Hawthorne Effect and Tracking Benefits (00:32:06) Current Trends and AI in Legal Marketing (00:33:49)You can find The Free Lawyer Assessment here- https://www.garymiles.net/the-free-lawyer-assessmentWould you like to learn what it looks like to become a truly Free Lawyer? You can schedule a complimentary call here: https://calendly.com/garymiles-successcoach/one-one-discovery-callWould you like to learn more about Breaking Free or order your copy? https://www.garymiles.net/break-free

Hosts Kevin Schwaller and Ema Sasic are ringing in the new year with a look back at 2025 in film and ranking their top 10 favorite movies of the year. Let's see what 2026 brings!Disclaimer:Copyright notice:(Intro/outro) She's The Greatest Dancer by Ryan Andersen is licensed under a Attribution-NonCommercial License. https://freemusicarchive.org/music/Ryan_Andersen/MORE/Shes_The_Greatest_Dancer?fbclid=IwAR1TDCO9eT6TxmDrTaJr9HRQVk2gUu00cNXeG8oik3avXVEhbSGqsqUfLkoCopyright notice:(Break) Extremely Tik-tok compatible for slow videos by Lundstroem is licensed under a Attribution 4.0 International License. https://freemusicarchive.org/music/lundstroem/the-happiest-songs/extremely-tik-tok-compatible-for-slow-videos/

In dieser Folge blicken wir ehrlich und nüchtern auf das Bitcoin-Jahr 2025 zurück. Wir sprechen darüber, warum viele Erwartungen – insbesondere rund um Preisentwicklung und Bullrun – nicht erfüllt wurden und weshalb nahezu alle Prognosen, auch unsere eigenen, danebenlagen. Der ausbleibende Hype, fehlendes Retail-Interesse sowie politische und regulatorische Themen standen dieses Jahr stärker im Fokus als Bitcoin selbst. Außerdem ordnen wir Entwicklungen wie die MiCA-Regulierung, den Einfluss von Staaten und Institutionen und die Frage nach dem Ende klassischer Bitcoin-Zyklen ein. Zum Abschluss geben wir einen vorsichtigen Ausblick auf 2026 und sprechen darüber, wie es mit dem Podcast weitergeht.

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

1:17:32 – Birmingham Pizza of the Sea Review – Holiday Edition – with Chad Bowers and Mike Boody. License for this track: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) (https://creativecommons.org/licenses/by-nc-nd/4.0/). Attribution: by Chad Bowers – more info at titfos.tumblr.com or onsug.com.

In this episode of the AdTechGod Pod, guests Aaron Goldman (Mediaocean), Tony Marlow (LG Ads), and Jackelyn Keller (Jackwell Partners) reflect on the past year in advertising, the impact of AI, and the trends shaping the future. The conversation covers everything from weird meetings in 2025 to the overhyped nature of AI and retail media. The guests share insights on the importance of understanding data, the challenges of attribution, and the need for creativity in marketing. The episode concludes with a rapid-fire round of questions, revealing personal opinions and humorous takes on the industry. Takeaways AI has significantly influenced all industries, not just advertising. Naming and branding can lead to intense discussions in meetings. AI-powered solutions are often overhyped in the industry. Retail media networks may struggle to survive without scale. Attribution methods in advertising are complex and often debated. Predictions in the industry can be unnecessary and overdone. Creative optimization is essential for effective marketing campaigns. Understanding data is crucial for marketers to make informed decisions. The future of advertising may involve more interactive and engaging ad formats. The importance of chilling out about industry drama and focusing on collaboration. Chapters 00:00 Welcome and ugly sweaters 03:40 50 Cent and NewFront prep 06:20 AI hype vs reality 08:45 Curation and other buzzwords 12:10 AdCP and why it is hard 14:30 Creative optimization A/B to A-Z 17:45 Ads inside AI chat experiences 18:45 Regifting trends, retail media, and clean rooms 22:10 Agentic commerce debate 25:40 What the industry should chill about 29:30 Rapid-fire questions 36:00 Wrap-up and holiday sign-off Learn more about your ad choices. Visit megaphone.fm/adchoices

O podcast de hoje é a grande celebração do trabalho de diferentes mulheres na indústria do cinema e da televisão desse ano: o Troféu Alice 2025, nosso prêmio de preferidos do ano. O programa é apresentado por Isabel Wittmann e Camila Henriques.Votaram, em ordem alfabética:Barbara Demerov: Site | LetterboxdBeatriz Saldanha: Site | LetterboxdCamila Henriques: Site | LetterboxdCarissa Vieira: Site | LetterboxdCarla Oliveira: Site | LetterboxdCarol Ballan: Site | Letterboxd Cecília Barroso: Site | Letterboxd Gabriela Larocca: Site | LetterboxdIeda Marcondes: Site | Letterboxd Isabel Wittmann: Site | Letterboxd Júlia Gavillan: Site | LetterboxdLarissa Paiva Maia: Site | Letterboxd Ligia Ferraz: Site | Letterboxd Maitê Mendonça: Site | LetterboxdMari Dertoni: Site | LetterboxdNatália Bocanera: Site | Letterboxd Pamela Eurídice: Site | LetterboxdRaíssa Basílio: Site | LetterboxdRaíssa Ferreira: Site | Letterboxd Stephania Amaral: Site | Letterboxd Tati Regis: Site | Letterboxd além de nossa audiência.A lista com todos os filmes premiados e votados pode ser conferida aqui.Feedback: contato@feitoporelas.com.brFeed | Bluesky | Instagram | Letterboxd | TelegramApresentação: Isabel Wittmann e Camila HenriquesPesquisa, pauta e roteiro: Isabel WittmannProdução do programa, edição de áudio, edição de vídeo e de vídeo e arte da capa: Isabel WittmannVinheta: Felipe Ayres Locução da vinheta: Deborah Garcia (deh.gbf@gmail.com)Música de encerramento: Bad Ideas - Silent Film Dark de Kevin MacLeod está licenciada sob uma licença Creative Commons, Attribution, Origem, Artista.Apoie nosso financiamento coletivo.Pix: contato@feitoporelas.com.brReferências completas no site: https://feitoporelas.com.br/feito-por-elas-209-trofeu-alice-2025-melhores-do-ano/

In this final Nicaragua episode, Laura travels to Granada the way so many locals do—by chicken bus. These colorful, chaotic former U.S. school buses are an experience in themselves, and the journey from Ometepe to Granada is filled with market noise, snack vendors, seat strategy, and a healthy dose of travel nostalgia.Once in Granada, Laura wanders the relaxed colonial streets of one of the oldest cities in the Americas, founded in 1524 and shaped by its proximity to Lake Nicaragua. Along the way, we dive into the city's layered history—from Spanish colonization to ambitious canal plans that never fully materialized, including the long-debated alternative to the Panama Canal. This episode blends solo travel moments with big-picture history, all set against the backdrop of one of Nicaragua's most beautiful cities.Musical Credits:Momentos by MusicBox and Hello Love by Jasmine J Walker provided by: Slipstream Music Support the showWant to support the podcast? Go to Laura's Patreon site to see photos from the episode, maps of places she talks about and you can become a patron too!Follow the show on instagram or facebook. Buy any of these products that I fully stand behind- and I'll earn a commission. Buy cute sustainable bags at: https://torrain.org/ Use Promo code: TRAVELALONG to get 15% off. Buy matcha at: https://mantramatcha.com/ Use Promo code: TRAVELALONG to get 15% off. Buy sustainably produced coffee: https://www.afueracoffee.com/ Enter promo code: TRAVELALONG for 15% off. Flowers by Cedric Galke x Fachhochschule Dortmund is licensed under a Attribution 4.0 International License.

Why Dec. 25? Why so much Christmas conflict & controversy in Christianity's history? Why is Christmas so important to Christianity? And to America? In this episode, I ask my guest, Dr. Carey Roberts, the following questions: ►Why is Christmas such a grand celebration? What does this tell us about Christianity? ►Did it take a while for Christmas to take a central role in Christianity►What's the difference between recognition and celebration of Christmas►Did Christmas piggyback on existing Roman pagan traditions? ►How did Christmas enter America's culture? If not the Puritans, then which immigrant group introduced Christmas to America? ►Were there any regional differences in the celebration of Christmas?►When did U.S. businesses begin to capitalize on Christmas? ►Would President Grant have witnessed a similar Christmas celebration in Boston and Savannah? ►Would George Washington recognize our Christmas? How about Andrew Jackson? Abraham Lincoln? Teddy Roosevelt? ►What happened to Christmas after WWII? ►Is it a bad thing that non-Christians and/or non-practicing Christians celebrate Christmas? ⁠

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

Welcome to episode 310 of Grow Your Law Firm, hosted by Ken Hardison. In this episode, Ken is joined by Jake Soffer, Founder and CEO of FirmPilot, an AI-driven marketing platform built to help law firms acquire more clients through intelligent automation and deep market data. Jake brings over a decade of experience in natural language processing and artificial intelligence, rooted in his computer engineering studies at RPI and NYU. Before founding FirmPilot, he built and exited companies in the NLP space and now leads one of the most advanced AI marketing systems in the legal industry—what he calls a "high-performing AI agency in a box." With FirmPilot now supporting more than 120 firms, Jake is at the forefront of how AI, competitive intelligence, and real-time data are reshaping the way legal practices grow. What you'll learn about in this episode: 1. How AI Content Really Works - What differentiates low-quality AI content from high-performing - Why models trained on legal sources outperform generic tools like ChatGPT 2. Using Market Data to Outperform Competitors - Why copying what you see your competitors doing will usually fail - How to analyze deeper signals like backlinks, markup, and behavioral data 3. Domain Authority and Backlinks - What domain authority really measures and how to interpret it - Why quality, consistency, and relevance in link building now outweigh volume 4. Attribution and Tracking in a Multi-Channel World - Why last-touch attribution no longer gives you the full picture - How Google Tag Manager and call-tracking create accurate marketing feedback loops 5. Preparing for the Future of AI Search - How generative engines like ChatGPT and Gemini evaluate legal expertise - Why optimizing for "fanned-out queries" and AI overviews is becoming essential Resources: Website: firmpilot.com LinkedIn: linkedin.com/in/jake-soffer-jd-00797a62 Facebook: facebook.com/p/FirmPilot-100092301576461 Instagram: instagram.com/firmpilot     Additional Resources:    https://www.pilmma.org/the-mastermind-effect https://www.pilmma.org/resources https://www.pilmma.org/mastermind AI for PI Expo:   www.pilmma.org/ai-for-pi-expo

Slay bells ring in 1980s London as Dave and Jon tackle Edmund Purdom et al's Don't Open till Christmas (1984). CW: Violence, gendered violence, problematic portrayals of LGBTIQ+ characters. Copyright © 2025 David Thomas and Jon Dear Availability on disc and streaming: Blu-ray.com Our theme music:Silent Night (Dark Piano Version) by myuu Creative Commons — Attribution 3.0 Unported— CC BY 3.0Free Download/Stream Music promoted by Audio Library Giallo Reading ListLa Dolce Morte: Vernacular Cinema and the Italian Giallo Film by Mikel J. Koven Italian Giallo in Film and Television: A Critical History by Roberto Curti So Deadly, So Perverse: 50 Years of Italian Giallo Films by Troy HowarthVolume 1: 1963-1973Volume 2: 1974-2013Volume 3: Giallo-Style Films From Around the World Mario Bava: All the Colours of the Dark by Tim Lucas Dario Argento: The Man, the Myths & the Magic by Alan Jones All the Colours of Sergio Martino by Kat Ellinger Beyond Terror: The Films of Lucio Fulci by Stephen Thrower Human Beasts: The Films of Paul Naschy by Troy Howarth Italian Horrors: Cannibals, Zombies, Strange Vices and Guilty Pleasures! edited by Allan Bryce Make Them Die Slowly: The Kinetic Cinema of Umberto Lenzi by Troy Howarth

Have you ever looked at a piece of religious art in your local church, a museum, or online and wonder how to interpret its meaning? Join Angela Sealana and her guest, Kathryn Laffrey of KL Art Studio as they discuss how Sacred art can lead us to greater hope and encouragement when we learn how to appreciate its significance. In this episode, you will discover: How did art become so important in Christian tradition? Why is art important for our mission as Christians, including care for the poor and vulnerable? What are the meanings of common sacred art symbols? How can viewing sacred art strengthen our hope? Continue Your Journey: Guest information and helpful resources. * Correction: Pope John Paul II wrote The Jeweller's Shop as Bishop Karol Wojtyła in 1960 during the threat of Communism in Poland, not during his underground theater days as implied by Angela during the discussion. Jewel for the Journey: "Not all are called to be artists in the specific sense of the term. Yet, as Genesis has it, all men and women are entrusted with the task of crafting their own life: in a certain sense, they are to make of it a work of art, a masterpiece." - Pope St. John Paul II Resurrection Stained Glass Window image Attribution, NateBergin, CC BY 4.0 Do you like what you hear? Become a Missionary of Hope by sponsoring a week of Journeys of Hope. Click here to get started. Learn more at https://pilgrimcenterofhope.org/media-and-resources/all-media-series/journeys-of-hope.html Help us spread hope! https://pilgrimcenterofhope.org/support

Find Merch here: https://theirrelevant.org/store Join The El Pochcast Discord here: https://discord.gg/AS8RuMHsxJ Bluesky: @elpochcast.pocho.online Instagram: @elpochcast Email : elpochcast@ gmail.com Text: www.pocho.online El Pochcast is a part of The Irrelevant Podcast Network rapture.mp3 by Vincent Augustus is licensed under a Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/ Support El Pochcast by contributing to their tip jar: https://tips.pinecast.com/jar/el-pochcast

Measuring marketing's impact is hard. There's no silver bullet. And if someone tells you there is, they're probably selling you something that only tracks clicks.This week, Elena, Angela, and Rob are joined by Chief Analytics Officer Matt Hultgren to tackle one of marketing's most persistent challenges: measurement. They explore why so many campaigns fail before they even launch, how to balance short-term performance with long-term brand building, and why the best marketers use multiple models to find the truth.Topics covered: [02:00] Why human behavior makes measurement messy[04:00] The planning problem causing measurement failures[06:00] Choosing your North Star metric[08:00] Balancing immediate CAC with long-term brand growth[10:00] Using multiple models to triangulate the truth[13:00] Quantifying TV's halo effect across channels[15:00] Incrementality testing vs MMM vs synthetic controls To learn more, visit marketingarchitects.com/podcast or subscribe to our newsletter at marketingarchitects.com/newsletter.  Resources: 2025 Marketing Architects Report: https://www.marketingarchitects.com/Long-and-Short  Get more research-backed marketing strategies by subscribing to The Marketing Architects on Apple Podcasts, Spotify, or wherever you listen to podcasts. 

It's an episode just absolutely full of fish! Thanks to Arthur, Yuzu, Jayson, Kabir, Nora, Siya, Joel, Elizabeth, Mac, Ryder, Alyx, Dean, and Riley for their suggestions this week! Further reading: Study uncovers mechanics of machete-like 'tail-whipping' in thresher sharks Business end of a sawfish: Giant freshwater stingray! The frilled shark looks like an eel: The frilled shark's teeth: The thresher shark and its whip-like tail [photo by Thomas Alexander - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=50280277]: The Halmahera epaulette shark, looking a little bit like a long skinny koi fish [photo by Mark Erdmann, California Academy of Sciences, Attribution, https://commons.wikimedia.org/w/index.php?curid=30260864]: A mudskipper, which is a fish even though it kind of looks like a weird frog [photo by Heinonlein - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=44502355]: The red-lipped batfish wants a big kiss: The male blue groper is very blue [photo by Andrew Harvey, some rights reserved (CC BY) - https://www.inaturalist.org/photos/62196538, CC BY 4.0, https://commons.wikimedia.org/w/index.php?curid=157789928]: The giant oarfish is very long: Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. This week we have a big fish episode! I mean, it's a big episode about a lot of different fish, not necessarily fish that are big—although some of them sure are! Thanks to Arthur, Yuzu, Jayson, Kabir, Nora, Siya, Joel, Elizabeth, Mac, Ryder, Alyx, Dean, and Riley. I told you this is a big fish episode. Let's jump right in with a fish suggested by Jayson, the sawfish. There are five species of sawfish alive today. The smallest can still grow over 10 feet long, or 3 meters, while the biggest species can grow over 20 feet long, or 6 meters. The largest sawfish ever reliably measured was 24 feet long, or 7.3 meters. The sawfish lives mostly in warm, shallow ocean waters, usually where the bottom is muddy or sandy. It can also tolerate brackish and even freshwater, and will sometimes swim into rivers and live there just fine. The sawfish is a type of ray, and rays are most closely related to sharks. Like sharks, rays have an internal skeleton made of cartilage instead of bone, but they also have bony teeth. You can definitely see the similarity between sharks and sawfish in the body shape, although the sawfish is flattened underneath, which allows it to lie on the ocean floor. There's also another detail that helps you tell a sawfish from most sharks: the rostrum, or snout. It's surprisingly long and studded with teeth on both sides, which makes it look like a saw. The teeth on the sawfish's saw are actual teeth. They're called rostral teeth and the rostrum itself is part of the skull, not a beak or a mouth. It's covered in skin just like the rest of the body. The sawfish's mouth is located underneath the body quite a bit back from the rostrum's base, and the mouth contains a lot of ordinary teeth that aren't very sharp. Since the sawfish has plenty of teeth in its mouth, you may be wondering how and why it also has extra teeth on both sides of its saw. It's because the rostral teeth evolved from dermal denticles. Dermal denticles look like scales but they're literally teeth, they're just not used for eating. Sharks have them too, along with some other fish. In the case of the sawfish, the rostral teeth grow much larger than an ordinary dermal denticle, and stick out sideways. Both the rostrum and the head are packed with electroreceptors that allow the sawfish to sense tiny electrical charges that animals emit as they move. This might mean a school of fish swimming through muddy water, or it might mean a crustacean hiding in the sand. The sawfish sometimes uses its rostrum to dig prey out of the sand, but it also uses it to slash at fish or other animals.

The party wraps up its investigation of Greengripe and makes a controversial deal with an enemy. Meanwhile, Mike needs a recon.WebsiteDiscordTwitterPathfinder Second Edition and the Kingmaker Adventure Path are published by Paizo."Take the Lead" and other featured music were composed by Kevin MacLeod and licensed under Creative Commons by: Attribution 4.0 License.All ambiances were composed by Michael Ghelfi Studios.The Zero Check are committed to providing an inclusive and respectful experience to all listeners, but we also recognize and acknowledge that we are limited by our individual frames of reference. If we misstep, please let us know. Email all feedback to feedback@zerocheckpodcast.com.Thank you for listening to The Zero Check. Send us a text

A wealthy British businessman living in colonial Egypt finds his comfortable life begin to unravel when he is haunted by the mysterious sound of footsteps that seem to follow him through the streets at night.This original recording is an audio presentation by Jasper L'Estrange for EnCrypted Horror. “THE STEP” by E.F. Benson, 1931.Supporting my workIf you like, you can donate in the following ways:Patreon: https://www.patreon.com/encryptedpodYouTube channel membership: https://www.youtube.com/c/EnCryptedClassicHorror/joinOne-off donation: https://ko-fi.com/encryptedpodcastYou can now also say THANKS (on YouTube) with a SUPER THANKS!LIKE, COMMENT, SHARE - it all helps the show survive and prosper!If you want to discuss the show, talk business, or have any ideas for stories you'd like to hear in future episodes, contact me: encryptedpod@gmail.com

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

Of Monsters and Mushrooms, Ch. 12 (book 1 NEW) ep. 809 The Literal Boulder from Indiana Jones NOTE: This is a rewrite of book 1. Originally, 'Of Monsters and Mushrooms' was supposed to be a multi-part short story that transformed halfway through into a novel. This left the plot (and the voice acting, to be honest) lacking. We decided to go back and completely rewrite book one to fix any plot holes and bring the quality in line with the rest of the series. Listen to the new book one playlist here https://talltaletv.com/series-of-monsters-and-mushrooms-new/ or Listen to book one (NEW!) https://talltaletv.com/series-of-monsters-and-mushrooms-new/ Listen to book two http://talltaletv.com/series-of-tyrants-and-teakettles/ Listen to book three http://talltaletv.com/series-of-bandits-and-bad-magic/ Listen to book 3.5 https://talltaletv.com/series-an-interlude-of-intrigue/ Listen to book four https://talltaletv.com/series-of-portals-and-portents/ Listen to book five https://talltaletv.com/series-of-risk-and-relativity/   Listen to the original book one http://talltaletv.com/series-monsters-mushrooms/   ---- Listen Elsewhere ---- YouTube:  https://www.youtube.com/c/TallTaleTV Website: http://www.TallTaleTV.com   ---- Story Submission ---- Got a short story you'd like to submit? Submission guidelines can be found at http://www.TallTaleTV.com   ---- About Tall Tale TV ---- Hi there! My name is Chris Herron and I'm an audiobook narrator. In 2015, I suffered from poor Type 1 diabetes control which lead me to become legally blind for almost a year. The doctors didn't give me much hope, predicting an 80% chance that I would never see again. But I refused to give up and changed my lifestyle drastically. Through sheer willpower (and an amazing eye surgeon) I beat the odds and regained my vision. During that difficult time, I couldn't read or write, which was devastating as they had always been a source of comfort for me since childhood. However, my wife took me to the local library where she read out the titles of audiobooks to me. I selected some of my favorite books, such as the Disc World series, Name of the Wind, Harry Potter, and more, and the audiobooks brought these stories to life in a way I had never experienced before. They helped me through the darkest period of my life and I fell in love with audiobooks. Once I regained my vision, I decided to pursue a career as an audiobook narrator instead of a writer. That's why I created Tall Tale TV, to support aspiring authors in the writing communities that I had grown to love before my ordeal. My goal was to help them promote their work by providing a promotional audio short story that showcases their writing skills to readers. They say the strongest form of advertising is word of mouth, so I offer a platform for readers to share these videos and help spread the word about these talented writers. Please consider sharing these stories with your friends and family to support these amazing authors. Thank you!   ---- legal ---- All stories on Tall Tale TV have been submitted in accordance with the terms of service provided on http://www.talltaletv.com or obtained with permission by the author. All images used on Tall Tale TV are either original or Royalty and Attribution free. Most stock images used are provided by http://www.pixabay.com , https://www.canstockphoto.com/ or created using AI. Image attribution will be declared only when required by the copyright owner. Common Affiliates are: Amazon, Smashwords

Natalia Chappell is the founder of Natalia Chappell & Co, a UK-based consultancy helping luxury and lifestyle brands scale sustainably. Previously, she led marketing for THG's luxury division, working with brands like Coach and Ralph Lauren across price points from hundreds to thousands of pounds.In this episode of DTC Pod, Natalia breaks down what it really takes for US brands to win in the UK—and why so many get it wrong. She shares the full-funnel mistakes she sees premium brands make over and over, why some household US names thrived in Britain while others quietly retreated, and what's actually driving results on Meta right now. She also gets into how to connect with younger consumers who think differently about spending, and why the old playbook of polished content isn't cutting it anymore. Plus, her journey from corporate marketing leader to female founder, and what she wishes more people understood about building a business as a woman.Episode brought to you by StordInteract with other DTC experts and access our monthly fireside chats with industry leaders on DTC Pod Slack.On this episode of DTC Pod, we cover:1. Lessons from high-growth UK e-commerce brands 2. Creating sustainable, holistic marketing strategies3. Using data and analytics to drive channel mix decisions4. Optimizing for paid and organic synergy5. Landing page and website audit best practices6. UGC, influencer, and creator partnership frameworks7. Onboarding and managing creators for conversion and brand fit8. Navigating UK logistics, customs, and local expectations9. How to adapt brand voice and content for UK consumer10. UK cultural moments and how to plan campaigns around them11. Success stories (Drunk Elephant, Ralph Lauren, Coach) and why some US brands flop12. Digital-first approaches to brand building13. Upcoming trends—partnership ads, authentic content, and Gen Z consumers14. Supporting and growing as a female founder in e-commerceTimestamps00:00 Introduction to DTC POD and episode with Natalia Chappell01:18 Natalia's background: fashion, digital marketing, luxury brand experience03:26 Lessons learned building luxury and beauty e-commerce teams05:16 Becoming a female founder and launching Natalia Chappell & Co07:22 The type and scale of brands Natalia's agency works with09:07 Optimizing paid-to-organic mix for sustainable growth12:12 Data, analytics, and the importance of first-party data integrity13:33 Why understanding inventory and offer depth matters before scaling ads16:26 Building a marketing flywheel that feeds itself18:50 Audience segmentation, CRM, and conversion optimization20:08 Attribution modeling and keeping data integrations clean22:29 Organic growth: auditing website, SEO, landing pages, and reviews24:03 Content strategy: authentic UGC, influencers, and the UK market26:58 Equipping creators for conversion, not just reach29:25 Structuring affiliate and creator programs, commissioning vs. flat fees33:01 Logistics: Warehousing, customs, and UK delivery expectations36:54 Adapting voice, copy, and calendar to resonate in the UK38:34 Brand case studies: Drunk Elephant, Coach, Ralph Lauren41:09 Why some US brands struggle in the UK (Forever 21, etc.)44:21 Trends to watch: partnership ads, content authenticity, Gen Z targeting47:25 Where to find and connect with Natalia ChappellShow notes powered by CastmagicPast guests & brands on DTC Pod include Gilt, PopSugar, Glossier, MadeIN, Prose, Bala, P.volve, Ritual, Bite, Oura, Levels, General Mills, Mid Day Squares, Prose, Arrae, Olipop, Ghia, Rosaluna, Form, Uncle Studios & many more.  Additional episodes you might like:• #175 Ariel Vaisbort - How OLIPOP Runs Influencer, Community, & Affiliate Growth• #184 Jake Karls, Midday Squares - Turning Your Brand Into The Influencer With Content• #205 Kasey Stewart: Suckerz- - Powering Your Launch With 300 Million Organic Views• #219 JT Barnett: The TikTok Masterclass For Brands• #223 Lauren Kleinman: The PR & Affiliate Marketing Playbook• ​​​​#243 Kian Golzari - Source & Develop Products Like The World's Best Brands-----Have any questions about the show or topics you'd like us to explore further?Shoot us a DM; we'd love to hear from you.Want the weekly TL;DR of tips delivered to your mailbox?Check out our newsletter here.Projects the DTC Pod team is working on:DTCetc - all our favorite brands on the internetOlivea - the extra virgin olive oil & hydroxytyrosol supplementCastmagic - AI Workspace for ContentFollow us for content, clips, giveaways, & updates!DTCPod InstagramDTCPod TwitterDTCPod TikTokNatalia Chappell - Founder of Natalia Chappell & Co.Blaine Bolus - Co-Founder of CastmagicRamon Berrios - Co-Founder of Castmagic

Find Merch here: https://theirrelevant.org/store Join The El Pochcast Discord here: https://discord.gg/AS8RuMHsxJ Bluesky: @elpochcast.pocho.online Instagram: @elpochcast Email : elpochcast@ gmail.com Text: www.pocho.online El Pochcast is a part of The Irrelevant Podcast Network rapture.mp3 by Vincent Augustus is licensed under a Attribution 4.0 International License. https://creativecommons.org/licenses/by/4.0/ Support El Pochcast by contributing to their tip jar: https://tips.pinecast.com/jar/el-pochcast

The party meets the leader of Greengripe, who accuses them of banditry.WebsiteDiscordTwitterPathfinder Second Edition and the Kingmaker Adventure Path are published by Paizo."Take the Lead" and other featured music were composed by Kevin MacLeod and licensed under Creative Commons by: Attribution 4.0 License.All ambiances were composed by Michael Ghelfi Studios.The Zero Check are committed to providing an inclusive and respectful experience to all listeners, but we also recognize and acknowledge that we are limited by our individual frames of reference. If we misstep, please let us know. Email all feedback to feedback@zerocheckpodcast.com.Thank you for listening to The Zero Check. Send us a text

Will Prime Minister Takaichi be a champion for women's rights?

"Working as an oncology infusion nurse, being oncology certified, attending chapter meetings, going to ONS Congress® has really taught me plenty. But being an oncology patient taught me way more. I know firsthand the fears 'you have cancer' brings. Then going through further testing, CT scans, MRIs, genetics, the whole preparation for surgery was something I never considered when I treated a breast cancer patient," ONS member Catherine Parsons, RN, OCN®, told Valerie Burger, MA, MS, RN, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about her experience being an oncology nurse and cancer survivor. Burger spoke with Parsons and ONS members Margaret Hopkins, MSN, RN, OCN®, HNB-BC, and Afton Dickerson, MSN, AGACNP-BCP, CBCN®, AOCNP®, CGRA, about how cancer survivorship has shaped their careers as oncology nurses and personal lives. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 385: ONS 50th Anniversary: Evolution of Cancer Survivorship Episode 263: Oncology Nursing Storytelling: Renewal Episode 253: The Ethics of Caring for People You Know Personally Episode 187: The Critical Need for Well-Being and Resiliency and How to Practice Episode 91: The Seasons of Survivorship ONS Voice articles: Being a Patient Taught Me How to Be a Better Oncology Nurse by Margaret Hopkins Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession Our Unified Voices Can Improve Cancer Survivorship Care Why I Truly Understand How Our Patients Hold Onto Hope ONS book: Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (third edition) ONS course: Essentials in Survivorship Care for the Advanced Practice Provider ONS Nurse Well-Being Learning Library ONS Huddle Cards: Coping Moral Resilience Survivorship Care Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Parsons: "I thought I knew cancer. I thought I knew the treatment. I thought I knew the side effects. There's so much I didn't know. There's so much behind the scenes before a patient comes and sits in my chair. The stuff that they go through I now can understand. It surprised me how much I didn't know." TS 11:39 Hopkins: "I had been thinking I'm going to be that hero, that I can go to work. I work at night, get 8 am radiation appointments, and go home and go to sleep and wake up and go to work again because everyone said, 'Oh, it's not that bad. Radiation will be okay. You can work.' … But the real challenge for me was I didn't know how to be a patient and a nurse at the same time. And my first radiation treatment, I go in there, and I change into the gown, and then I started cleaning up because I was getting treatment done at the hospital where I worked, and were taught if you see a mess, you clean it. So I was acting like a nurse. And I almost wanted to go help the other patients, but I couldn't because I had to focus on healing." TS 15:36 Dickerson: "What made the difference for me were the nurses who didn't just treat my illness. They treated me as a whole person—my emotions, my feelings. They made me smile. They would hold my hand or just take a moment to really ask, 'Hey, how are you?' And those small, little gestures made me feel worthy, made me feel like a human. I always tell nurses it's not just about the chemo; it's about the connection. Sometimes your presence is the most healing thing that you can offer to your patient." TS 30:52

This is 22 Hours: A Second Look, where we revisit our original season with host Megan Cloherty. In this episode, you'll hear what happened when Megan reached out to Daron Wint in prison. You'll learn just how many prisons he's been transferred to in the last 10 years, why he filed suit while he was inside, and what it takes to communicate with a prisoner in a federal penitentiary.New episodes drop every Tuesday.Original Episode-After Daron Wint's conviction, federal prosecutors press the judge for the harshest possible sentence and, for the first time reveal his history of explosive rage, violent threats and assaults. At Daron's sentencing, emotional statements from the two surviving Savopoulos daughters are read in court. As the last regular episode comes to a close, we reflect back.This episode is written and produced by reporters Megan Cloherty and Jack Moore. Julia Ziegler is the content adviser. "22 Hours: An American Nightmare" is a production of WTOP News in Washington, D.C. All music featured in "22 Hours: An American Nightmare" is licensed through Creative Commons and/or by permission of the artist. We're grateful to all the artists whose music has helped us tell this story. Music for this episode is “Haters Hate” by Ramone Messam; “Beyond the Lows” by The Whole Other and “Spookster” by Wayne Jones, available in the YouTube Audio Library. “Rhythmic Pulse” and “Closing my Eyes for a Moment” by Daniel Birch and “Harbor” by Kai Engel are licensed under Creative Commons by Attribution 4.0 International.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.